Department of Microbiology and Immunology
News...Tomlinson Receives Second VA Merit
Stroke is the third leading cause of death in the United States and the main cause of long-term disability. Studies proposed investigate injury and repair mechanisms after stroke using mouse models and clinically relevant pharmacologic agents (complement inhibitors). The work is expected to elucidate antibody and complement dependent mechanisms of injury and recovery after stroke, and to lead to the development of a therapeutic agent that will improve long-term cognitive and functional recovery after stroke.
This is Dr. Tomlinson's second VA Merit as PI. He has previously received funds from other VA Merits as Co-Investigator prior to becoming an independent VA Researcher. Additionally, Dr. Tomlinson was recently awarded three patents:
1. Tissue targeted complement modulators (US 8,454,963 B2)
2. Complement receptor 1 and 2 fusion proteins (US 8,540,997 B2)
3. Targeting complement factor H for treatment of diseases (US 8,569,225 B2)